Clinical Trial Update: A Study in Children With Different Formulations of GSK Biologicals' 11 Valent Pneumococcal Conjugate Vaccine [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating different formulations of GlaxoSmithKline's 11-valent pneumococcal conjugate vaccine in children has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Streptococcal Infections

Drugs mentioned

• Pneumococcal Conjugate Vaccine, 11-valent (pneumococcal conjugate vaccine, 11-valent)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Streptococcal Infections | Phase 2 | Status: COMPLETED